스위스 - 이탈리아어 - Swissmedic (Swiss Agency for Therapeutic Products)

bristol-myers squibb sa - nivolumabum - concentrato per soluzione per infusione - nivolumabum 40 mg, natrii citras dihydricus, natrii chloridum, mannitolum, acidum penteticum, polysorbatum 80, acidum hydrochloridum, natrii hydroxidum, aqua ad iniectabile q.s. ad solutionem pro 4 ml corresp. natrium 10 mg. - onkologikum - biotechnologika

스위스 - 이탈리아어 - Swissmedic (Swiss Agency for Therapeutic Products)

bristol-myers squibb sa - nivolumabum - concentrato per soluzione per infusione - nivolumabum 100 mg, natrii citras dihydricus, natrii chloridum, mannitolum, acidum penteticum, polysorbatum 80, acidum hydrochloridum, natrii hydroxidum, aqua ad iniectabile q.s. ad solutionem pro 10 ml corresp. natrium 25 mg. - onkologikum - biotechnologika

스위스 - 이탈리아어 - Swissmedic (Swiss Agency for Therapeutic Products)

bristol-myers squibb sa - elotuzumabum - polvere per soluzione per infusione - elotuzumabum 300 mg, natrii citras dihydricus corrisp. sodio 3.9 mg, acido citricum monohydricum, zucchero, polysorbatum 80 per il vetro. - multipli myelom - biotechnologika

스위스 - 이탈리아어 - Swissmedic (Swiss Agency for Therapeutic Products)

bristol-myers squibb sa - elotuzumabum - polvere per soluzione per infusione - elotuzumabum 400 mg, natrii citras dihydricus corrisp. sodio 5.3 mg, acido citricum monohydricum, zucchero, polysorbatum 80 per il vetro. - multipli myelom - biotechnologika

스위스 - 이탈리아어 - Swissmedic (Swiss Agency for Therapeutic Products)

bristol-myers squibb sa - nivolumabum - concentrato per soluzione per infusione - nivolumabum 240 mg, natrii citras dihydricus, natrii chloridum, mannitolum, acidum penteticum, polysorbatum 80, acidum hydrochloridum, natrii hydroxidum, aqua ad iniectabile q.s. ad solutionem pro 24 ml corresp. natrium 60 mg. - onkologikum - biotechnologika

유럽 연합 - 이탈리아어 - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - ozanimod hydrochloride - multiple sclerosis, relapsing-remitting; colitis, ulcerative - immunosoppressori - multiple sclerosiszeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (rrms) with active disease as defined by clinical or imaging features. ulcerative colitiszeposia is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.

유럽 연합 - 이탈리아어 - EMA (European Medicines Agency)

bristol myers squibb pharma eeig - luspatercept - anemia; myelodysplastic syndromes; beta-thalassemia - altre antianemico preparazioni - reblozyl is indicated for the treatment of adult patients with transfusion-dependent anaemia due to very low, low and intermediate-risk myelodysplastic syndromes (mds) with ring sideroblasts, who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy (see section 5. reblozyl is indicated in adults for the treatment of anaemia associated with transfusion dependent and non transfusion dependent beta thalassaemia (see section 5.

유럽 연합 - 이탈리아어 - EMA (European Medicines Agency)

bristol myers squibb pharma eeig - fedratinib dihydrochloride monohydrate - myeloproliferative disorders; primary myelofibrosis - agenti antineoplastici - inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are janus associated kinase (jak) inhibitor naïve or have been treated with ruxolitinib.

유럽 연합 - 이탈리아어 - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - azacitidina - leucemia, mieloide, acuta - agenti antineoplastici - onureg is indicated as maintenance therapy in adult patients with acute myeloid leukaemia (aml) who achieved complete remission (cr) or complete remission with incomplete blood count recovery (cri) following induction therapy with or without consolidation treatment and who are not candidates for, including those who choose not to proceed to, hematopoietic stem cell transplantation (hsct).

유럽 연합 - 이탈리아어 - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - agenti antineoplastici - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.